This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E72.0 (Lowe syndrome) | Special Copayment Reduction: V117 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | Oculocerebrorenal syndrome (OCRS), OCRL1 deficiency, phosphatidylinositol 4,5-bisphosphate 5-phosphatase deficiency (PI(4,5)P₂-5-phosphatase deficiency), Lowe oculocerebrorenal syndrome, continuous spectrum with Dent-2 disease |
| C. Adult onset | Likelihood of first onset in adulthood very low — congenital cataracts and hypotonia are already evident at birth or in the neonatal period, so most cases are diagnosed in infancy; in carrier females, punctate posterior subcapsular cataracts are sometimes first found in adulthood; a first diagnosis of an affected individual in adulthood is extremely exceptional. |
| 1. History | 1952 first description by Lowe, Terrey, and MacLachlan (cataracts, hypotonia, renal acidosis) → 1992 OCRL1 gene localized to Xq26 → 1995 identification of PI(4,5)P₂-5-phosphatase → 2000s elucidation of its role in vesicle trafficking → 2009 continuous spectrum with Dent-2 confirmed. |
| 2. Causes | Mutations in the OCRL gene on the long arm of the X chromosome (Xq26.1). Deficiency of the OCRL1 protein (PI(4,5)P₂-5-phosphatase) → excessive endosomal PI(4,5)P₂ accumulation → blockade of the megalin/cubilin reabsorption pathway in the proximal tubule → damage to three systems: ocular, neurological, and renal. |
| 3. Genetics | X-linked recessive. OCRL gene (Xq26.1), 24 exons. Many point mutations, small deletions, and splicing variants. Punctate posterior subcapsular cataracts characteristic in carrier females. Allelic disorder of the same gene as Dent-2 disease. |
| 4. General epidemiology | About 1 in 500,000 male births. About 600 people registered worldwide (NORD 2023). Being X-linked, affected individuals are virtually all male. Case reports exist in Korea. |
| 5. Pathophysiology | OCRL1 deficiency → excess PI(4,5)P₂ → impaired clathrin vesicle uncoating and endosomal trafficking → loss of megalin recycling → Fanconi syndrome. Abnormal actin arrangement in lens cells → congenital cataracts. Impaired neuronal growth cone migration → intellectual disability. |
| 6. Symptoms | Three cardinal symptoms: ① congenital bilateral cataracts (100%), ② severe hypotonia, ③ renal Fanconi syndrome (growth failure, rickets). Additional: intellectual disability (moderate to severe), behavioral disorders, glaucoma (~50%), polyarticular swelling. |
| 7. Signs | Nuclear bilateral cataracts on slit lamp. Absent deep tendon reflexes, proximal weakness. Urine: glucosuria, aminoaciduria, low-molecular-weight proteinuria. Serum: hypophosphatemia, hypokalemia, metabolic acidosis. Creatinine elevation with CKD progression. |
| 8. Screening | Boys with a family history: eye examination + urinalysis (glucosuria, aminoaciduria) + serum electrolytes at birth. Carrier females: slit-lamp examination (punctate cataracts). Direct analysis of the OCRL gene. Prenatal: genetic testing after CVS/amniocentesis. |
| 9. Diagnosis | Clinical diagnosis by the combination of the three cardinal clinical symptoms. Confirmation: NGS analysis of the OCRL gene. Exon deletions: MLPA. Enzyme activity measurement (reduced leukocyte OCRL1 activity). Differential: Dent-2, cystinosis, mitochondrial disease. |
| 10. Treatment | No fundamental treatment. Cataracts: early surgery (weeks to months after birth). Glaucoma: ocular hypotensive agents, surgery. Fanconi syndrome: sodium bicarbonate, potassium citrate, phosphate, calcitriol. Seizures: anticonvulsants. Rehabilitation: physical, occupational, and speech therapy. ESRD: kidney transplantation. |
| 11. Prognosis | Survival into adulthood possible but with serious morbidity. 84% of those aged 20 or older at CKD stage 4~5 (2024 cohort). 67% of those aged 30 or older with ESRD. Intellectual disability mostly moderate to severe. Kidney transplantation is the standard treatment for ESRD. |
| 12. Prevention | Primary: genetic counseling of carrier females, prenatal/PGT-M. Secondary: early cataract surgery (preventing amblyopia), immediate electrolyte correction (preventing rickets), early detection of glaucoma (eye examination every 6 months). Tertiary: delaying CKD progression with RAAS blockers, integrated multidisciplinary follow-up. |
| 13. References | Charnas LR et al. N Engl J Med. 1991 … and 9 other papers |
Lowe syndrome was first named in 1952 when the American pediatrician Charles U. Lowe (1921–2012), together with his colleagues M. Terrey and E. A. MacLachlan, described a combination of clinical symptoms in three boys: congenital cataracts, hypotonia, mental retardation, renal acidosis, and aminoaciduria. Because the syndrome involves three systems—ocular, cerebral, and renal—Lowe named it "oculocerebrorenal syndrome (OCRS)."
From the 1960s onward, the renal dysfunction of this syndrome was confirmed to be a subtype of Fanconi syndrome, and in the 1980s the X-linked recessive mode of inheritance was systematically established. In 1992, Wauters et al. mapped the OCRL1 gene to the Xq26 region on the long arm of the X chromosome, and in 1995 Bottomley et al. identified the OCRL1 protein as a phospholipid 5-phosphatase located in the trans-Golgi network, establishing the molecular basis.
In the 2000s, it was found that OCRL1, as a catalyst converting PI(4,5)P₂ to PI4P, plays a key role in regulating intracellular vesicle trafficking, tubular protein reabsorption, and ciliary function. In particular, in 2009 Utsch et al. reported that mild OCRL variants with only renal symptoms and no ocular or neurological involvement are classified as "Dent-2 disease" and form a continuous spectrum with Lowe syndrome caused by the same gene, drawing attention to the diversity of clinical phenotypes. In the 2020s, studies are visualizing in real time how OCRL1 deficiency disrupts vesicle trafficking in proximal tubule cells in patient-derived iPSC-based kidney organoid models, and preclinical research toward gene correction and targeted therapy is active.
The sole cause of Lowe syndrome is pathogenic variants in the OCRL gene located on the long arm of the X chromosome (Xq26.1). The OCRL gene consists of 24 exons and encodes the OCRL1 protein (molecular weight about 105 kDa), composed of about 968 amino acids.
OCRL1 has a multidomain structure: an N-terminal PH domain (phospholipid binding, membrane targeting), a central 5-phosphatase catalytic domain (PI(4,5)P₂ → PI4P conversion), an ASH (ASPM-SPD-2-Hydin) domain (protein–protein interaction), and a RhoGAP homology domain (Rac1/Cdc42 binding). This protein regulates vesicle trafficking pathways by removing the 5'-phosphate group of PI(4,5)P₂ in the Golgi apparatus, early endosomes, and clathrin-coated vesicles.
More than 200 pathogenic variants of the OCRL gene have been reported, mostly point mutations (missense, nonsense), small deletions/insertions, and splicing variants. Genotype–phenotype correlations are not clear, but variants in the 5-phosphatase domain are mainly associated with the full Lowe syndrome phenotype, while ASH domain variants appear in both Lowe syndrome and mild Dent-2 disease. This is an example of diverse variants in the same gene determining a phenotypic spectrum.
Lowe syndrome follows an X-linked recessive mode of inheritance. The OCRL gene is located at Xq26.1 on the long arm of the X chromosome and is about 49 kb in size. Because it is X-linked recessive, affected individuals are virtually all male. In males, an OCRL pathogenic variant on the X chromosome results in full expression of the disease.
Female carriers have a variant on only one of their two X chromosomes and are usually clinically asymptomatic, but posterior subcapsular or cortical punctate cataracts are observed on slit-lamp examination in about 90%. This carrier eye finding is useful for noninvasive carrier identification. Mild renal tubular dysfunction may appear in some carrier females with skewed X-inactivation (skewed lyonization).
Among the children of a carrier mother, 50% of sons are affected and 50% of daughters become carriers. About 30% of patients arise from de novo mutations and have no family history. In genetic counseling, the key elements are identification of carrier females, estimation of recurrence risk, and offering preimplantation genetic testing (PGT-M) or prenatal diagnosis options. Diagnosis is made by NGS-based single-gene testing or an X-linked rare disease gene panel, and exon-level deletions/duplications are confirmed by MLPA.
Lowe syndrome is a very rare X-linked rare disease worldwide, with a reported incidence of about 1 in 500,000 male births. According to the US National Organization for Rare Disorders (NORD), about 600 registered patients are known worldwide, and the actual number is presumed to be larger when undiagnosed patients are included. Because of X-linked recessive inheritance, affected individuals are almost exclusively male. Expression in females has been reported only in exceptional situations such as accompanying Turner syndrome (45,X) or severely skewed X-inactivation.
No regional or ethnic differences in incidence are known, and it occurs with the same frequency worldwide. In Korea, some patients are managed through the rare disease Special Copayment Reduction (V117) registration system, but accurate domestic prevalence statistics have not been published. It must be differentiated in boys presenting to pediatric ophthalmology or pediatric nephrology clinics with the combined symptoms of congenital cataracts and renal tubular dysfunction.
An international multicenter cohort study published in 2024 confirmed that 84% of patients with Lowe syndrome aged 20 or older had reached chronic kidney disease stage 4~5, and 67% of those aged 30 or older had progressed to end-stage renal disease (ESRD). Accordingly, kidney transplantation is becoming the main treatment step around the age of 30. Because of intellectual disability and behavioral problems, independent living is mostly impossible, and a lifelong support system is needed.
The core of the molecular pathogenesis of Lowe syndrome is excessive intracellular accumulation of PI(4,5)P₂ due to loss of OCRL1 enzyme function. OCRL1 normally regulates intracellular vesicle trafficking pathways by converting PI(4,5)P₂ to PI4P in the Golgi apparatus and early endosomes.
Renal pathogenesis: proximal tubular epithelial cells reabsorb proteins from the glomerular filtrate by clathrin-mediated endocytosis via megalin (LRP2) and cubilin. In OCRL1 deficiency, PI(4,5)P₂ is not removed from endocytosed vesicles, so clathrin uncoating and endosomal trafficking stop. As a result, cell-surface recycling of megalin/cubilin is blocked, reabsorption of amino acids, glucose, phosphate, and low-molecular-weight proteins is broadly lost, and Fanconi syndrome is complete.
Lens pathogenesis: in lens epithelial cells, excessive PI(4,5)P₂ accumulation damages actin cytoskeletal rearrangement and cell junctions, disrupting the normal arrangement of lens fiber cells, so lens opacity (congenital cataracts) occurs from birth.
Neurological pathogenesis: PI(4,5)P₂ signaling balance is essential for neuronal growth cone migration and synaptic vesicle recycling. When PI(4,5)P₂ accumulates excessively due to OCRL1 deficiency, excessive actin polymerization → impaired growth cone motility → abnormal neural wiring → intellectual disability and behavioral abnormalities result. Excessive formation of F-actin branches is also observed in skin fibroblasts.
The clinical symptoms of Lowe syndrome progress in a combined manner from birth to adulthood, centered on three systems: ocular, neurological, and renal.
Ocular symptoms: congenital bilateral cataracts are already present in utero in virtually 100% of patients and require surgery in the neonatal period. The cataracts are usually dense nuclear opacities, and residual visual impairment remains even after early surgery. Nystagmus appears as sensory-deprivation and motor types and interferes with visual development. Glaucoma develops after the first year of life in about 50% of all patients, causing elevated intraocular pressure and optic nerve damage.
Neurological symptoms: severe infantile hypotonia causes prominent feeding difficulty and delayed motor development. Intellectual disability ranges from mild to severe but is mostly moderate to severe, and language development is markedly delayed. Reported behavioral disorders include repetitive behaviors, self-injury, hyperactivity, and tantrums, and some patients show autism spectrum features. Seizures occur in some patients.
Renal and metabolic symptoms: polyuria, polydipsia, growth failure, rickets, and metabolic acidosis due to Fanconi syndrome appear from infancy. Chronic kidney disease (CKD) progresses slowly and often reaches ESRD in the 20s~30s.
Joint and musculoskeletal symptoms: polyarticular swelling, pain, and limited range of motion are commonly observed in adult patients. When osteomalacia and hypophosphatemia accompany them, the risk of bone pain and pathological fractures increases. Scoliosis also occurs in some.
The physical signs of Lowe syndrome reflect involvement of the three systems and provide key clues for diagnosis.
Ophthalmic signs: bilateral nuclear cataracts are confirmed on slit-lamp examination. Elevated intraocular pressure (glaucoma, about 50% of all). Optic disc pallor on funduscopy (advanced glaucoma). In carrier females, punctate posterior subcapsular opacities are observed in about 90%.
Neurological signs: generalized reduction or absence of deep tendon reflexes. Proximal weakness (quadriceps, upper arm). Gait abnormalities, impaired coordination. Markedly delayed language development. Seizures in some.
Renal signs: positive glucose (with normal blood glucose) and protein on urine dipstick. On quantitative urine analysis, generalized aminoaciduria and markedly elevated β2-microglobulin (tubular proteinuria). Serum electrolytes: hypophosphatemia (1.5~2.5 mg/dL), hypokalemia. Blood gas: normal anion gap metabolic acidosis. Elevated BUN and creatinine (with CKD progression).
Growth and musculoskeletal signs: growth failure with weight and height below the 3rd percentile for age. Rachitic findings on lower limb X-rays (irregular epiphyses, bowing of long bones). Scoliosis. Joint swelling, tenderness, and limited range of motion.
There is no population-wide screening program for Lowe syndrome; targeted screening of at-risk groups and families is key.
Newborn and infant screening (with a family history): in newborn boys in families with an identified OCRL variant, eye examination (slit lamp, intraocular pressure measurement) and basic urinalysis (glucosuria, aminoaciduria) are performed immediately after birth. Serum electrolytes (phosphate, potassium, bicarbonate) and blood gas are measured together.
Screening of carrier females: because of X-linked inheritance, OCRL gene analysis and slit-lamp examination are performed in the mother, maternal grandmother, maternal aunts, older sisters, and others of a patient with Lowe syndrome. When punctate cataracts are found, the woman is regarded as a carrier and pregnancy planning counseling is begun.
Screening based on clinical suspicion: when congenital bilateral cataracts are found in a boy, or in a boy with confirmed renal Fanconi syndrome, the combination with neurodevelopmental and ophthalmic abnormalities is evaluated immediately. When the history suggests possible X-linked inheritance, OCRL gene testing is performed early.
Regular monitoring: after confirmation, serum creatinine, urine protein/creatinine ratio, and serum phosphate, potassium, and bicarbonate are measured every 3~6 months to follow renal function. Intraocular pressure is evaluated every 6 months and the fundus at least once a year.
Lowe syndrome is clinically diagnosed by the combination of the three cardinal clinical symptoms and confirmed by OCRL gene analysis.
Clinical diagnostic criteria: in male patients, a clinical diagnosis is possible when all three of the following are met: ① congenital bilateral cataracts, ② severe infantile hypotonia, ③ renal Fanconi syndrome (glucosuria, aminoaciduria, hypophosphatemia, metabolic acidosis). Intellectual disability, behavioral disorders, and glaucoma are supportive findings.
Molecular genetic diagnosis: pathogenic variants are identified by NGS analysis of the OCRL gene (single-gene testing or an X-linked rare disease panel). Exon-level deletions/duplications are detected by MLPA. If no variant is found, splicing abnormalities can be identified by whole-genome sequencing (WGS) or RNA analysis.
Enzyme activity testing: deficiency can be confirmed by measuring OCRL1 (PI(4,5)P₂-5-phosphatase) enzyme activity in leukocytes or skin fibroblasts, but because access to this test is limited, genetic analysis takes priority.
Differential diagnosis: Dent-2 disease (OCRL variants but mild ocular and neurological symptoms), Fanconi syndrome due to galactosemia, cystinosis, mitochondrial diseases, and Donnai-Barrow syndrome (LRP2 variants) are differentiated. Distinction from other genetic diseases with congenital cataracts (Nance-Horan syndrome, Cantu syndrome, etc.) is also needed.
There is currently no fundamental treatment for Lowe syndrome, and intensive symptomatic management of each of the three systems (ocular, neurological, renal) is the basis of treatment.
Ophthalmic treatment: for congenital cataracts, early surgery within a few weeks to 2 months after birth is recommended for visual development. Postoperative aphakia is corrected with glasses or contact lenses, and amblyopia training is started immediately. Glaucoma is managed with ocular hypotensive eye drops (beta-blockers, carbonic anhydrase inhibitors, prostaglandin analogs) and surgical treatment (trabeculectomy, aqueous drainage device implantation).
Renal and metabolic treatment: electrolyte correction for Fanconi syndrome is carried out continuously over the long term. Sodium bicarbonate or potassium citrate (correction of acidosis, target HCO₃⁻ >18 mEq/L), sodium and potassium phosphate (correction of hypophosphatemia), calcitriol (0.25~0.5 μg/day, prevention and treatment of rickets), and potassium supplementation (hypokalemia). If oral supplementation is insufficient, tube feeding or gastrostomy is considered. With CKD progression, RAAS blockers are tried to reduce proteinuria and protect the kidneys. In ESRD, kidney transplantation is the standard treatment, and systemic symptoms persist after transplantation.
Neurological and developmental treatment: early intensive rehabilitation is key. Physical therapy (strength and motor development), occupational therapy (daily function), and speech therapy (improving communication) are started from a few months of age. Anticonvulsants are individualized for seizures. For behavioral disorders, behavioral therapy and environmental structuring are the main approaches, combined with low-dose medication when needed. Special education and lifelong support services are needed.
The prognosis of Lowe syndrome is generally poor because of severe multisystem involvement, but active symptomatic management can prolong life and improve quality of life.
Renal prognosis: in a 2024 international cohort study, 84% of patients aged 20 or older progressed to CKD stage 4~5 and 67% of those aged 30 or older to ESRD. Kidney transplantation is the standard treatment for ESRD; renal function recovers after transplantation, but systemic symptoms persist. Adequate electrolyte treatment and correction of acidosis can slow CKD progression.
Visual prognosis: despite early cataract surgery, severe visual impairment remains in a considerable number. When glaucoma develops, optic nerve damage accumulates despite treatment, with a risk of blindness. Nystagmus interferes with visual development.
Neurodevelopmental prognosis: intellectual disability is mostly moderate to severe, and independent living is almost impossible. Behavioral disorders (self-injury, hyperactivity) persist into adulthood, imposing a heavy care burden. Augmentative and alternative communication (AAC) devices are useful for patients whose verbal expression is severely limited.
Survival prognosis: with appropriate supportive care, survival into the 40s~50s has been reported. The main causes of death are infection, complications of ESRD, and severe metabolic abnormalities.
Prevention of Lowe syndrome focuses on genetic counseling, preimplantation and prenatal genetic diagnosis, and preventing progression of complications.
Primary prevention: comprehensive genetic counseling for families of patients with Lowe syndrome is key. Slit-lamp examination and OCRL gene analysis are performed to identify carrier females. Preimplantation genetic testing (PGT-M) or prenatal diagnosis (OCRL gene analysis after CVS/amniocentesis) is offered to identified carrier females. Because about 30% arise from de novo mutations, genetic testing is performed immediately in boys showing the triple combination of congenital cataracts, hypotonia, and tubular dysfunction even without a family history.
Secondary prevention: early surgery for congenital cataracts (recommended within 6~8 weeks after birth) prevents sensory-deprivation amblyopia and maximizes visual development. Glasses or contact lenses are prescribed and amblyopia training is started immediately after surgery. Electrolyte supplementation (sodium bicarbonate, phosphate, calcitriol) is started immediately upon diagnosis to prevent progression of rickets and growth failure. Intraocular pressure is checked every 6 months to detect glaucoma early.
Tertiary prevention: CKD progression and proteinuria are suppressed with RAAS blockers (ACE inhibitors or ARBs). Blood pressure is maintained below 130/80 mmHg. Function is maximized through early rehabilitation and behavioral therapy for intellectual and behavioral disabilities. A multidisciplinary team of pediatric nephrology, ophthalmology, neurology, genetics, and rehabilitation medicine provides integrated follow-up every 3~6 months.
Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA. Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe. N Engl J Med. 1991;324(19):1318–1325. DOI: 10.1056/NEJM199105093241904 PMID: 2017234.
Hichri H, Rendu J, Monnier N, et al. From Lowe syndrome to Dent disease: correlations between mutations of the OCRL1 gene and clinical and biochemical phenotypes. Hum Mutat. 2011;32(4):379–388. DOI: 10.1002/humu.21391 PMID: 21120943.
Mehta ZB, Pietka G, Lowe M. The cellular and physiological functions of the Lowe syndrome protein OCRL1. Traffic. 2014;15(5):471–487. DOI: 10.1111/tra.12160 PMID: 24450426.
Zaniew M, Bokenkamp A, Kolbuc M, et al. Long-term renal outcome in children with OCRL mutations. Nephrol Dial Transplant. 2018;33(1):85–94. DOI: 10.1093/ndt/gfw275 PMID: 27387476.
Ramirez IB, Lowe M. Oculocerebrorenal syndrome of Lowe: OCRL and the control of PtdIns(4,5)P(2) levels. FEBS Lett. 2009;583(20):3253–3260. DOI: 10.1016/j.febslet.2009.09.012 PMID: 19737564.
Tosetto E, Rizzo M, Ammenti A, et al. Lowe syndrome: Italian long-term follow-up study. J Nephrol. 2021;34(4):1059–1064. DOI: 10.1007/s40620-020-00807-z PMID: 32627141.
Bokenkamp A, Ludwig M. The oculocerebrorenal syndrome of Lowe: an update. Pediatr Nephrol. 2016;31(12):2201–2212. DOI: 10.1007/s00467-016-3343-3 PMID: 27084011.
Kenworthy L, Park T, Charnas LR. Cognitive and behavioral profile of the oculocerebrorenal syndrome of Lowe. Am J Med Genet. 1993;46(3):297–303. DOI: 10.1002/ajmg.1320460313 PMID: 8488869.
Bockenhauer D, van't Hoff W, Dattani M, et al. OCRL mutations in Lowe syndrome and Dent-2 disease. J Pediatr Genet. 2012;1(1):15–23. DOI: 10.3233/PGE-2012-004
Ye YY, Chen XY, Zhang W. Novel OCRL mutations and early-onset renal failure in Chinese patients with Lowe syndrome. Pediatr Nephrol. 2019;34(12):2523–2531. DOI: 10.1007/s00467-019-04312-1 PMID: 31451941.